Perspective

Journal of Medicinal and Organic Chemistry

Small Molecule RNA Modulators: Expanding the Therapeutic Frontier

Priya Nair*

Dept. of Medicinal Chemistry, Bharat Science Univ, India

*Author for correspondence: pnair@bsu.in

Received: 01-Oct-2025, Manuscript No. jmoc-26-184931; **Editor assigned:** 03-Oct-2025, PreQC No. jmoc-26-184931 (PQ); **Reviewed:** 18-Oct-2025, QC No. jmoc-26-184931; **Revised:** 21-Oct-2025, Manuscript No. jmoc-26-184931 (R); **Published:** 31-Oct-2025, DOI: 10.37532/jmoc.2025.8(5).316-317

Introduction

RNA has emerged as a central player in gene regulation, protein synthesis, and cellular signaling, making it an attractive target for therapeutic intervention. Small molecule RNA modulators are designed to selectively bind RNA structures, altering their function and influencing disease-associated pathways. Unlike traditional protein-targeted drugs, RNA modulators offer the potential to regulate previously "undruggable" targets, providing innovative strategies for treating genetic disorders, viral infections, and cancers [1-5].

Discussion

Small molecule RNA modulators operate by interacting with specific RNA motifs, such as hairpins, bulges, loops, and pseudoknots, to influence RNA stability, folding, or interactions with proteins. These interactions can either inhibit or enhance RNA function, enabling precise modulation of gene expression. For example, modulators targeting microRNAs (miRNAs) can suppress oncogenic signaling, while compounds targeting viral RNA structures can block replication.

The discovery and optimization of RNA-targeting small molecules rely on a combination of high-throughput screening, structure-based design, and computational modeling. Techniques such as fluorescence-based assays, surface plasmon resonance, and NMR spectroscopy are commonly used to identify molecules that bind RNA with high affinity and selectivity. Once initial hits are identified, medicinal chemistry strategies refine binding specificity, metabolic stability, and pharmacokinetic properties.

Small molecule RNA modulators offer several advantages over other therapeutic approaches. They can access intracellular targets without the need for complex delivery systems, unlike oligonucleotide-based therapies. Additionally, their small size allows oral bioavailability and the potential for systemic administration. Clinically, RNA-targeted modulators are being explored in areas such as neurodegenerative diseases, viral infections, and cancer, with several preclinical candidates demonstrating potent and selective effects on RNA-mediated pathways.

Challenges remain in targeting RNA with small molecules, including the structural flexibility of RNA, potential off-target interactions, and achieving sufficient intracellular concentrations. Advances in RNA structural biology, chemical library design, and RNA-targeted screening platforms are helping overcome these limitations, enabling the rational development of more selective and effective modulators.

Conclusion

Small molecule RNA modulators represent a promising frontier in drug discovery, enabling precise regulation of gene expression and RNA-mediated pathways. By targeting RNA structures previously considered undruggable, these compounds provide novel therapeutic strategies for cancer, viral diseases, and genetic disorders. Continued advancements in screening technologies, computational modeling, and chemical design

will expand the potential of RNA-targeted therapies, offering innovative, effective, and versatile treatments for complex diseases.

References

1. Praveen Kumar (2012) A stability indicating RP-HPLC method development for determination of Ezetimibe in tablet dosage form. Der Pharma Chemica 4: 1296-1304.
2. Raul (2015) RP-HPLC Method Development and Validation for the Simultaneous Estimation of Atorvastatin and Ezetimibe in Pharmaceutical Dosage Form. Asian J Pharm Clin Res 8: 178-181.
3. El-Bagary (2014) LC-MS-MS Simultaneous Determination of Atorvastatin and Ezetimibe in Human Plasma. Journal of Chromatographic Science 52:773-780.
4. Suneela D, Dhaneshwar S, Deshpande P, Patil M (2007) Development and validation of a method for simultaneous densitometric estimation of Atorvastatin calcium and Ezetimibe as the bulk drug and in tablet dosage forms. Acta Chromatographica 19: 141-148.
5. Danafar H (2016) High performance liquid chromatographic method for determination of Ezetimibe in pharmaceutical formulation tablets. Pharmaceutical and Biomedical Research 2: 38-46.